India, July 24 -- Outlook Therapeutics (OTLK) announced that the FDA has approved LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of neovascular age-related macular degeneration (wet AMD).
Wet AMD is a leading cause of vision loss in older adults, driven by abnormal blood vessel growth in the retina. For years, physicians relied on repackaged intravenous bevacizumab for eye injections, which lacked FDA approval for ophthalmic use.LYTENAVA now provides a purpose-built, regulated formulation designed specifically for intravitreal administration, ensuring consistency and quality oversight.
The approval follows years of clinical trials and regulatory review, granting LYTENAVA 12 years of mar...